Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines

Clinical and Diagnostic Laboratory Immunology

Volumn 3, Issue 4, 1996, Pages 378-386

  Gorse, Geoffrey J ^a,d   Patel, Gira B ^a   Newman, Frances K ^a   Belshe, Robert B ^a   Berman, Phillip W ^b   Gregory, Timothy J ^b   Matthews, Thomas J ^c   Schwartz, David ^e   Lambert, Jack ^e   Clements, Mary Lou ^e   Frey, Sharon E ^a   Mulligan, Mark ^f   Hook, Edward ^f   Evans, Thomas ^g   Keefer, Michael ^g   Dolin, Raphael ^g   McElrath, Julie ^h   Corey, Lawrence ^h   Graham, Barney S ⁱ   Wright, Peter ⁱ   Matthews, Thomas ^c   Bolognesi, Dani ^c   McNamara, James ^j   Walker, Mary Clare ^j   Fast, Patricia ^j   more..

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENENTECH INC   (United States)

^c DUKE UNIVERSITY   (United States)

^d S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ VANDERBILT UNIVERSITY   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MEMBRANE PROTEIN; PLACEBO; RECOMBINANT VACCINE;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS CHARACTERIZATION;

EID: 10244263660     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.3.4.378-386.1996     Document Type: Article

References (8)

1. Belshe, R. B., M. L. Clements, R. Dolin, B. S. Graham, J. McElrath, G. J. Gorse, D. Schwartz, M. C. Keefer, P. Wright, L. Corey, D. P. Bolognesi, T. J. Matthews, D. M. Stablein, F. S. O'Brien, M. Eibl, F. Dorner, W. Koff, and the National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. 1993. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J. Infect. Dis. 168:1387-1395.
2. Belshe, R. B., B. S. Graham, M. C. Keefer, G. J. Gorsc, P. Wright, R. Dolin, T. Matthews, K. Weinhold, D. P. Bolognesi, R. Sposto, D. M. Stablein, T. Twaddell, P. W. Berman, T. Gregory, A. E. Izu, M. C. Walker, and P. Fast, for the NIAID AIDS Vaccine Clinical Trials Network. 1994. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 272:475-180.
3. Berman, P. W., D. J. Eastman, D. M. Wilkes, G. R. Nakamura, T. J. Gregory, D. Schwartz, G. Gorse, R. Belshe, M. L. Clements, and R. A. Byrn. 1994. Comparison of the immune response to recombinant gp120 in humans and chimpanzees. AIDS 8:591-601.
4. Berman, P. W., T. J. Gregory, L. Riddle, G. R. Nakamura, M.A. Champe, J. P. Porter, F. M. Wurm, R. D. Hershberg, E. K. Cobb, and J. W. Eichberg. 1990. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (London) 345:622-625.
5. Berman, P. W., T. J. Matthews, L. Riddle, M. Champe, M. R. Hobbs, G. R. Nakamura, J. Mercer, D. J. Eastman, C. Lucas, A. J. Langlois, F. M. Wurm, and T. J. Gregory. 1992. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J. Virol. 66:4464-4469.
6. Cummins, L. M., K. J. Weinhold,T. J. Matthews, A. J. Langlois, C. F. Perno, R. M. Condie, and J.-P. Allain. 1991. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood 77:1111-1117.
7. Dolin, R., B. S. Graham, S. B. Greenberg, C. O. Tacket, R. B. Belshe, K. Midthun, M. L. Clements, G. J. Gorse, B. W. Horgan, R. L. Atmar, D. T. Karzon, W. Bonnez, B. F. Fernie, D. C. Montefiori, D. M. Stablein, G. E. Smith, W. C. Koff, and the NIAID AIDS Vaccine Clinical Trials Network. 1991. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann. Intern. Med. 114:119-127.
8. Dowbenko, D., G. Nakamura, C. Fennie, C. Shimasaki, L. Riddle, R. Harris, T. Gregory, and L. Lasky. 1988. Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies. J. Virol. 62:4703-4711.